Medical/Pharmaceuticals News & Press Release Distribution

Medical/Pharmaceuticals

APAC
Global

ZYMFENTRA® (infliximab-dyyb) coverage continues to increase through partnership with top 3 Pharmacy Benefit Managers (PBMs)

* Celltrion USA has expanded access to ZYMFENTRA® (infliximab-dyyb), the first and only FDA-approved subcutaneous (SC) infliximab, to a significant share of the U.S. market * The availability of ZYMFENTRA will support greater patient access and choice while helping to drive greater affordabil...

2024-10-31 14:31 1013

CStone Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UK

* This approval marks the second international marketing authorization for sugemalimab outside ofChina, following its recent approval by the European Commission. * The approval is based on results from the Phase 3 GEMSTONE-302 clinical trial, which demonstrated that sugemalimab in combination...

2024-10-31 13:00 1872

Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) Third NDA Accepted by NMPA, locally advanced or metastatic EGFR-mutant NSCLC

CHENGDU, China, Oct. 31, 2024 /PRNewswire/ -- The new drug application (NDA) (the "Application") based on the positive results from the pivotal phase III OptiTROP-Lung04 study of sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) developed by Sichuan Kelun-Biotech Biopharmaceutical Co., L...

2024-10-31 12:34 1550

Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) Third NDA Accepted by NMPA, locally advanced or metastatic EGFR-mutant NSCLC

2024-10-31 12:02 1452

Breakthrough Australian Cancer trial: retraining immune cells offers new hope for patients

ADELAIDE, Australia and BOSTON, Oct. 31, 2024 /PRNewswire/ -- In a remarkable development for cancer research, Australian patients with advanced-stage cancer have benefited from SUPLEXA, a personalised treatment that trains the patient's own immune cells to fight cancer. "Cancer often gains th...

2024-10-31 12:00 1659

MGI's DNBSEQ-T20 x2 Selected As A Special Mention In TIME Best Inventions 2024

SHENZHEN, China, Oct. 30, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI") , a company committed to building core tools and technologies that drive innovation in life science, is thrilled to announce that its DNBSEQ-T20x2 Genetic Sequencer* has been recognized as a Specia...

2024-10-31 10:51 1334

MGI's DNBSEQ-T20 x2 Selected As A Special Mention In TIME Best Inventions 2024

Abionic's CAPSULE PSP Receives FDA Approval for Early Detection of Sepsis; Fapon Introduces Exclusive PSP Solution in China via Licensing Collaboration

DONGGUAN, China, Oct. 30, 2024 /PRNewswire/ -- Fapon, a global leading life sciences company, is thrilled to announce its PSP CLIA reagent solution which demonstrates promising outcomes in extensive clinical validation studies targeting Chinese population. Leveraging its strategic partnership ...

2024-10-31 10:26 1290

Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combined with Ligufalimab (CD47) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma (HNSCC), Compared to Pembrolizumab

HONG KONG, Oct. 30, 2024 /PRNewswire/ -- Akeso Biopharma (9926.HK) is pleased to announce the enrollment of the first patient in its randomized, controlled, multicenter Phase III clinical study (AK117-302) for head and neck squamous cell carcinoma. This trial evaluates the innovative PD-1/VEGF bi...

2024-10-31 08:46 1941

RapidAI Applauded by Frost & Sullivan for Enhancing the Quality, Accuracy, and Speed of Stroke Imaging Diagnostics and Treatment, Demonstrating Its Market-leading Position

RapidAI's leadership is evident in its expansive global presence, pioneering regulatory achievements, and continuous innovation, ensuring the company remains at the forefront of AI-based imaging solutions. SAN ANTONIO, Oct. 31, 2024 /PRNewswire/ -- Recently Frost & Sullivan researched the AI-bas...

2024-10-31 01:50 1496

RapidAI Applauded by Frost & Sullivan for Enhancing the Quality, Accuracy, and Speed of Stroke Imaging Diagnostics and Treatment, Demonstrating Its Market-leading Position

Latest Updates of Viva Biotech's Portfolio Companies

HONG KONG, Oct. 30, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the suc...

2024-10-30 22:24 1935

Telix Partners with Subtle Medical on AI-Enabled SubtlePET™ Software for Faster PET Imaging with Illuccix®

MELBOURNE, Australia, Oct. 30, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a partnership with California-based Subtle Medical, Inc. (Subtle Medical) for artificial intelligence (AI)-powered positron emission tomography (PET) imaging with Telix...

2024-10-30 21:27 1854

Neurophet partners with Beijing LADO Technology… Intends to establish Joint Venture in China

* Neurophet enters into a strategic agreement with LADO to distribute Neurophet SCALE PET * Improves the efficiency of market entry with expertise of medical device go-to-market process inChina through the establishment of joint venture SEOUL, South Korea, Oct. 30, 2024 /PRNewswire/ -- Neurop...

2024-10-30 21:00 1444

Neurophet partners with Beijing LADO Technology… Intends to establish Joint Venture in China

I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024

- Poster to be presented in a late-breaking abstract session at the Society for Immunotherapy of Cancer (SITC) onSaturday, November 9, 2024 ROCKVILLE, Md., Oct. 30, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company exclusively focused on the develop...

2024-10-30 19:00 996

World Stroke Congress | TASTE-2 significantly reduces stroke disability

NANJING, China, Oct. 30, 2024 /PRNewswire/ -- Oct 24th 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that a new clinical study with major clinical findings regarding Sanbexin (edaravone and dexborneol concentrated solution for injection) has been published at the 16th World Stroke...

2024-10-30 15:36 1233

World Stroke Congress | TASTE-2 significantly reduces stroke disability

Teijin and Hilleman Laboratories to Expand Business in Asia-Pacific via Strategic Partnership to Promote CDMO Services in Cell and Gene Therapy

SINGAPORE, Oct. 30, 2024 /PRNewswire/ -- Teijin Limited and Hilleman Laboratories , a biotechnology company based inSingapore, announced today the signing of a Memorandum of Understanding, for the establishment of a strategic international bu...

2024-10-30 15:00 1628

Teijin and Hilleman Laboratories to Expand Business in Asia-Pacific via Strategic Partnership to Promote CDMO Services in Cell and Gene Therapy

Pulsenmore Expands Partnership with Clalit Health Services to Deliver 25,000 Home Ultrasound Devices for Remote Prenatal Care

RAMAT GAN, Israel, Oct. 30, 2024 /PRNewswire/ -- Pulsenmore (TASE: PULS), a pioneering provider of home-based ultrasound technology, has announced the renewal and expansion of its strategic partnership with Clalit Health Services, Israel's largest HMO. Over the next five years, Pulsenmore will sup...

2024-10-30 14:00 1003

Pulsenmore Expands Partnership with Clalit Health Services to Deliver 25,000 Home Ultrasound Devices for Remote Prenatal Care

Fosun Pharma Announces 2024Q3 Financial Results

Revenue Exceed RMB30.9 Billion with R&D Expenditure RMB3.9 Billion Continuing to Consolidate its Dominant Position In The fields of Breast Cancer and Lung Cancer SHANGHAI, Oct. 29, 2024 /PRNewswire/ -- On October 29, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group";...

2024-10-30 10:41 1616

WuXi AppTec Named Global CRDMO Company of the Year by Frost & Sullivan for the Eighth Consecutive Year

SHANGHAI, Oct. 29, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, has been awarded the 2024 Global CRDMO Company of the Year Award by Frost & Sullivan, a gr...

2024-10-30 08:00 1176

Celltrion presents post hoc analysis of LIBERTY studies of ZYMFENTRA®  (infliximab-dyyb) at the American College of Gastroenterology 2024 Annual Scientific Meeting

* Pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) previously demonstrated superior efficacy of subcutaneous (SC) infliximab over placebo for maintenance therapy in patients with Crohn's disease (CD) and ulcerative colitis (UC)[1], [2] * ZYMFENTRA® is the first and only FDA-approved subcut...

2024-10-30 03:25 1224

DeepQure Presents Clinical Results of Laparoscopic RDN at TCT 2024, Demonstrating Cutting-edge Technology and Innovation

SEOUL, South Korea, Oct. 29, 2024 /PRNewswire/ -- DeepQure, a global pioneer in resistant hypertension treatment, has unveiled clinical results of its laparoscopic renal denervation (RDN) medical device "HyperQure". Designed to treat resistant hypertension,HyperQure uses a laparoscopic approach t...

2024-10-29 21:00 1448

1 ... 7 8 91011 12 13 ... 610